SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to a memorandum of understanding with the U.S. Department of Energy to advance quantum technologies in space, spurring discussions about the company's expanding footprint and potential government contracts. While some community members express concerns about valuation and profitability, others are bullish, drawing comparisons to other high-growth tech stocks and anticipating a potential short squeeze. The conversation also includes the broader context of quantum computing's role in the future of technology.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending as part of a broader surge in quantum computing stocks, with community members actively discussing its potential for significant gains. Optimism stems from upcoming events, potential government contracts, and the company's technology for optimization, though some express concerns about the current valuation. Overall, there's a sense of FOMO (fear of missing out) driving interest in QBTS.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders react to recent Fed moves, with some believing rate cuts are bullish while others anticipate a potential pullback. Community discussions revolve around whether the market is in a sustainable uptrend or a "ponzi scheme", and how to best play the current environment with calls or puts. Sentiment appears mixed, with both bulls and bears actively participating in the conversation.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo is trending due to speculation around its low float, potential for a short squeeze, and comparisons to other high-flying stocks with similar setups like $QMMM. Traders are actively discussing the possibility of a significant price surge, drawing parallels to past pumps and the stock's AI potential. The community is closely watching for a potential breakout, with some mentioning the company's small float and high short interest.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending as investors discuss its increasing Ethereum holdings and potential benefits from staking rewards. Community members are actively debating price targets and the impact of Ethereum's performance on BMNR, with some drawing comparisons to MicroStrategy's investment strategy. The stock is garnering attention as a leveraged play on the anticipated growth of Ethereum and the broader crypto market.

BGM Group Ltd. is a pharmaceutical and chemical company. It focuses on the research, development, manufacture, marketing, and sale of oxytetracycline products, licorice products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Licorice products include Gan Di Xin, Qilian Shan Licorice Extract, and Qilian Shan Licorice Liquid Extract. The Oxytetracycline products consists of Qilian Shan Oxytetracycline Tablets and Qilian Shan Oxytetracycline Active Pharmaceutical Ingredients (API). The TCMD product includes Ahan antibacterial paste, which is made from a mixture of traditional Chinese herbal ingredients. The heparin product includes Heparin Sodium Preparations. The Sausage Casings products include Zhu Xiaochang Sausage Casings, which are all-natural food products used for culinary purposes. The Fertilizer products is composed of Xiongguan Organic Fertilizer and Xiongguan Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Chengdu, China.

BGM Group Ltd. - Ordinary Shares - Class A

BGM Group Ltd

BGM Group (BGM) is trending due to strong community interest in its AI pivot and recent earnings report, which highlighted revenue growth driven by AI and insurance businesses. Community members are closely watching key technical levels and institutional accumulation, speculating on potential catalysts for a breakout. The stock's unique combination of AI, fintech, and robotics is generating discussion about its long-term potential and comparison to other high-growth AI companies.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors react to news of partnerships and positive milestones, with some highlighting its potential in the quantum computing sector. The community is actively discussing the company's progress toward commercial viability and comparing it to sector peers. Despite discussions of profitability, many see RGTI as a long-term play with significant potential.

Bullish engages in the management of a digital asset platform. It also offers market infrastructure and information services. The company was founded by Brendan Francis Blumer in 2020 and is headquartered in George Town, Cayman Islands.

Bullish

Bullish is trending following the announcement of securing a BitLicense from the New York State Department of Financial Services, seen by the community as a significant step for U.S. expansion. Community members are also discussing the firm's earnings report, which beat analyst estimates. Some traders are expressing optimism for potential upgrades and a continued rally, while others remain cautious, citing past performance and broader market conditions.

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

89bio Inc

89bio is trending following news of its acquisition by Roche, driving excitement and speculation about the future of the MASH space. The community is discussing the potential $20.50 per share value for shareholders and what this acquisition means for other companies in the sector, with some highlighting $ETNB's long downtrend before the buyout news. Community members are now looking for the next potential buyout target in the biotech space.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares

SOXS is trending as traders discuss its continued decline despite some semi stocks showing weakness, with community members expressing frustration over the ETF's tracking and potential manipulation. Some are hoping for a market correction or hawkish comments from the Fed to provide a catalyst for a reversal. Others are speculating about potential impacts from upcoming earnings and economic data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet

The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 122.2% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stocks to Buy for July 15th

FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025.

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?

The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

New Strong Buy Stocks for July 15th

FUTU, PAAS, RAPT, HG and IVZ have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2025.

Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's  What You Should Know

Clear Street initiated coverage of Rapt Therapeutics with a Buy rating and set a $3 price target, as the research firm has “strong conviction” in RPT904b as the company's candidate for the treatment of food allergy and chronic spontaneous urticaria (CSU).Shares of Rapt Therapeutics closed flat at $1.02 on Thursday, but rose 7.8% to $1.10 in after-hours trading.Clear Street said that RPT904b represents a "potentially best-in-class anti-IgE antibody" that rivals Xolair, the treatment jointly offered by Roche and Novartis.The firm also noted that Rapt shares have declined 76% over the past 12 months, compared to a 12% drop in the XBI biotech ETF, attributing the drop to an unrelated asset discontinuation.&nbsp;According to Clear Street, this has created a "significant opportunity" for investors.According to Rapt Therapeutics, RPT904b is a half-life extended monoclonal antibody designed to bind free human IgE, a central player in allergic inflammatory diseases.&nbsp;In early-stage trials, the candidate has shown extended pharmacokinetics and pharmacodynamics relative to Xolair, potentially enabling dosing every 8 to 12 weeks, compared to 2 to 4 weeks for omalizumab.&nbsp;It also aims to treat patients with high IgE levels or body weights who may not qualify for existing anti-IgE therapies.On May 22, UBS reduced its price target for Rapt Therapeutics to $1 from $2, while keeping its ‘Neutral’ rating unchanged.&nbsp;The research note from UBS said that the in-licensing of RPT904 as an omalizumab "bio-better" stands as a principal long-term asset for Rapt.UBS raised concerns about the short-term visibility of the addressable market but acknowledged that, although food allergy represents significant commercial potential, identifying the specific patient group in which RPT904 will show meaningful clinical results remains challenging.Meanwhile, H.C. Wainwright launched coverage for Rapt with a ‘Buy’ rating and established a $6 price target on the same day.&nbsp;The research firm highlighted RPT904 as an IgE blocker that follows a commercially validated approach to minimize target risk, referencing the proven effectiveness of omalizumab in treating food allergy, as well as asthma and chronic spontaneous urticaria cases.On Stocktwits, retail sentiment was ‘bearish’ amid ‘low’ message volume.A user expressed worries about the biotech’s cash runway.<stembedurl>https://stocktwits.com/Disrupter/message/617013073</stembedurl>The stock has declined 37.4% so far in 2025.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position

Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.”

Equity

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$18.00
Prev Close	$17.63
Open	$17.73
Dividend Yield	0.00%
50-Day Moving Average	$11.59
Beta	1.79
Avg. Volume	104,135.38
PE Ratio	-1.24

52-Week High	$26.56
52-Week Low	$5.67
Market Capitalization	$291.56M
EPS (Annual)	-$25.49
Price to Book	1.77
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

RAPT
RAPT Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RAPT News

RAPT RAPT Therapeutics Inc